Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology

被引：2

作者：

Brieva, Luis ^{[1
]}

Estruch, Bonaventura Casanova ^{[2
]}

Merino, Juan Antonio Garcia ^{[3
]}

Meca-Lallana, Virginia ^{[4
,5
]}

Rio, Jordi

Rodriguez-Antigueedad, Alfredo ^{[6
]}

Aguera, Eduardo ^{[7
]}

Ara, Jose Ramon ^{[8
]}

Luque, Adrian Ares ^{[9
]}

Garcia, Carmen Arnal ^{[10
]}

Blanco, Yolanda ^{[11
]}

Castillo-Trivino, Tamara ^{[12
]}

Costa-Frossard, Lucienne ^{[13
]}

Platas, Montserrat Gonzalez ^{[14
]}

Pascual, Lamberto Landete ^{[15
]}

Llaneza-Gonzalez, Miguel ^{[16
]}

Gines, Maria Luisa Martinez ^{[17
]}

Matias-Guiu, Jorge ^{[18
]}

Meca-Lallana, Jose E. ^{[19
]}

Bilbao, Mar Mendibe ^{[6
]}

Sempere, Angel Perez ^{[20
]}

Romero-Pinel, Lucia ^{[21
]}

Saiz, Albert ^{[22
]}

Moral, Ester ^{[23
,24
]}

机构：

[1] IRBLLEIDA, Hosp Arnau Vilanova, Lleida, Spain

[2] Hosp Universitari i Politecn Fe, Dept Neurol, Unit Neuroimmunol, Valencia, Spain

[3] Univ Autonoma Madrid, Fdn Invest Puerta Hierro, Madrid, Spain

[4] Hosp Univ Princesa, Dept Neurol, Multiple Sclerosis Unit, Madrid, Spain

[5] Hosp Univ Vall dHebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya, Serv Neurol Neuroimmunol, Barcelona, Spain

[6] Hosp Univ Cruces, Neuroimmunol & Multiple Sclerosis Unit, Baracaldo, Spain

[7] IMIBIC, Hosp Univ Reina Sofia, Neurol, Cordoba, Spain

[8] IIS Aragon, Hosp Univ Miguel Servet, Zaragoza, Spain

[9] Complejo Asistencial Univ Leon, Neurol, Leon, Spain

[10] Hosp Virgen Nieves, Granada, Spain

[11] Hosp Clin Barcelona, Un Neuroimmunol & Esclerosis multiple, Barcelona, Spain

[12] Biodonostia Hlth Res Inst, Neurol Dept, Basque Hlth Serv, Neurosci Area,Multiple Sclerosis Grp, San Sebastian, Spain

[13] Hosp Univ Ramon & Cajal, Fdn Invest Biomed IRyCIS, Serv Neurol, CSUR Esclerosis Multiple, Madrid, Spain

[14] Hosp Univ Canarias, Serv Neurol, Tenerife, Spain

[15] Hosp Univ Dr Peset, Serv Neurol, Valencia, Spain

[16] Complejo Hospitalario Univ Ferrol, Serv Neurol, La Coruna, Spain

[17] Hosp Gen Univ Gregorio Maranon, Serv Neurol, Madrid, Spain

[18] Univ Complutense Madrid, Hosp Clin San Carlos, Hlth Res Inst San Carlos IdISCC, Dept Neurol, Madrid, Spain

[19] IMIB Arrixaca, Hosp Clin Univ Virgen Arrixaca, Neurol Dept, CSUR Multiple Sclerosis & Clin Neuroimmunol Unit, Murcia, Spain

[20] Hosp Gen Univ Alicante, Neurol Serv, Alicante 03010, Spain

[21] Hosp Universitari Bellvitge IDIBELL, Dept Neurol, Multiple Sclerosis Unit, Lhospitalet De LLobregat, Barcelona, Spain

[22] Univ Barcelona, Hosp Clin, Inst Invest Biome August Pi Sunyer IDIBAPS d, Ctr Neuroimmunol, Barcelona, Spain

[23] Hosp Moises Broggi, Serv Neurol, Sant Joan Despi, Barcelona, Spain

[24] Hosp Gen Hospitalet, Serv Neurol, Lhospitalet De Llobregat, Barcelona, Spain

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2022年 / 63卷

关键词：

Relapsing multiple sclerosis; Disease modifying therapy; Benefit-risk; Therapy switching; Relapse; Washout period; INTERFERON-BETA; NATALIZUMAB; FINGOLIMOD; GUIDELINES; PREGNANCY; OUTCOMES; IMPACT; MRI;

D O I：

10.1016/j.msard.2022.103805

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: The increase in available disease modifying therapies (DMTs) for multiple sclerosis has led to greater emphasis on improving treatment sequencing paradigms. This article summarises the opinions from a panel of 25 experts on treatment switching approaches in relapsing multiple sclerosis (RMS).Methods: A modified Delphi consensus process was carried out to develop clinically relevant statements for aiding treatment decisions in patients with RMS between the 16th January and the 9th October 2019. A sub-group of two experts (core group) carried out an extensive review of the literature and formulated 106 statements for the expert panel to evaluate.Results: From a total number of 106 statements that were submitted to the expert panel for critical evaluation, consensus (at least 80% of the panelists agreed) was reached on 99 of them. These statements cover treatment objectives, reasons for DMT switching, suboptimal response criteria, strategies for treatment change and washout periods.Conclusion: The agreed statements provide up-to-date guidance on DMT sequencing for optimal patient management.

引用

页数：8

共 50 条

[31] Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis
Roos, I.
Malpas, C. B.
Leray, E.
Buzzard, K.
Skibina, O.
Lechner-Scott, J.
McCombe, P.
Slee, M.
Butler, E.
Macdonell, R.
van der Walt, A.
Hodgkinson, S.
Barnett, M.
Vucic, S.
Vukusic, S.
Butzkueven, H.
Kalincik, T.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 : 6 - 7
[32] Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
Diego Centonze
Maria A. Rocca
Claudio Gasperini
Ludwig Kappos
Hans-Peter Hartung
Melinda Magyari
Celia Oreja-Guevara
Maria Trojano
Heinz Wiendl
Massimo Filippi
Journal of Neurology, 2021, 268 : 3961 - 3968
[33] Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
Centonze, Diego
Rocca, Maria A.
Gasperini, Claudio
Kappos, Ludwig
Hartung, Hans-Peter
Magyari, Melinda
Oreja-Guevara, Celia
Trojano, Maria
Wiendl, Heinz
Filippi, Massimo
JOURNAL OF NEUROLOGY, 2021, 268 (11) : 3961 - 3968
[34] Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis
Chylinska, Magdalena
Komendzinski, Jakub
Wyszomirski, Adam
Karaszewski, Bartosz
MULTIPLE SCLEROSIS INTERNATIONAL, 2023, 2023
[35] Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis
Gajofatto, A.
Bacchetti, P.
Grimes, B.
High, A.
Waubant, E.
MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (01) : 50 - 58
[36] A prospective study of disease modifying therapy and retinal atrophy in relapsing-remitting multiple sclerosis
Kabanovski, Anna
Zaslavsky, Kirill
Rotstein, Dalia
Margolin, Edward
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 446
[37] Intense immunosuppression as the initial disease-modifying therapy in clinically active relapsing multiple sclerosis
Perumal, Jai
Hreha, Stephanie
Caon, Christina
Bao, Fen
Penmesta, Ramya
Tselis, Alexandros
Zak, Imad
Khan, Omar
MULTIPLE SCLEROSIS, 2008, 14 : S172 - S172
[38] Disease-modifying therapy in multiple sclerosis: recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society
Kulakowska, Alina
Mirowska-Guzel, Dagmara
Kalinowska, Alicja
Bartosik-Psujek, Halina
Brola, Waldemar
Stasiolek, Mariusz
Glabinski, Andrzej
Losy, Jacek
Potemkowski, Andrzej
Rejdak, Konrad
Sarzynska-Dlugosz, Iwona
Siger, Malgorzata
Stepien, Adam
Wawrzyniak, Slawomir
Zaborski, Jacek
Zakrzewska-Pniewska, Beata
Adamczyk-Sowa, Monika
NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2024, 58 (06) : 569 - 585
[39] Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
Roos, Izanne
Malpas, Charles
Leray, Emmanuelle
Casey, Romain
Horakova, Dana
Havrdova, Eva Kubala
Debouverie, Marc
Patti, Francesco
De Seze, Jerome
Izquierdo, Guillermo
Eichau, Sara
Edan, Gilles
Prat, Alexandre
Girard, Marc
Ozakbas, Serkan
Grammond, Pierre
Zephir, Helene
Ciron, Jonathan
Maillart, Elisabeth
Moreau, Thibault
Amato, Maria Pia
Labauge, Pierre
Alroughani, Raed
Buzzard, Katherine
Skibina, Olga
Terzi, Murat
Laplaud, David Axel
Berger, Eric
Grand'Maison, Francois
Lebrun-Frenay, Christine
Cartechini, Elisabetta
Boz, Cavit
Lechner-Scott, Jeannette
Clavelou, Pierre
Stankoff, Bruno
Prevost, Julie
Kappos, Ludwig
Pelletier, Jean
Shaygannejad, Vahid
Yamout, Bassem, I
Khoury, Samia J.
Gerlach, Oliver
Spitaleri, Daniele L. A.
Van Pesch, Vincent
Gout, Olivier
Turkoglu, Recai
Heinzlef, Olivier
Thouvenot, Eric
McCombe, Pamela Ann
Soysal, Aysun
NEUROLOGY, 2022, 99 (17) : E1926 - E1944
[40] Switching first-line disease-modifying therapy for relapsing-remitting multiple sclerosis in non-responders: is it a successful strategy?
Gajofatto, A.
Bacchetti, P.
Grimes, B.
High, A.
Moraes, C.
Waubant, E.
MULTIPLE SCLEROSIS, 2007, 13 : S45 - S45

← 1 2 3 4 5 →